Abbreviations
Commonly used abbreviations on this site.
| Abbreviation | Description |
|---|---|
| 10vPCV | 10-valent pneumococcal conjugate vaccine |
| 13vPCV | 13-valent pneumococcal conjugate vaccine |
| 23vPPV | 23-valent pneumococcal polysaccharide vaccine |
| 2vHPV | bivalent HPV vaccine |
| 4vHPV | quadrivalent HPV vaccine |
| 4vMenCV | quadrivalent meningococcal conjugate vaccine |
| 4vMenPV | quadrivalent meningococcal polysaccharide vaccine |
| 7vPCV | 7-valent pneumococcal conjugate vaccine |
| ABLV | Australian bat lyssavirus |
| ACT | Australian Capital Territory |
| ADRS | Adverse Drug Reactions System |
| AEFI | adverse event following immunisation |
| AIDS | acquired immunodeficiency syndrome |
| AIDS | acquired immunodeficiency syndrome |
| anti-HBc | antibody to hepatitis B core antigen |
| anti-HBe | antibody to hepatitis B e antigen |
| anti-HBs | antibody to hepatitis B surface antigen |
| AOM | acute otitis media |
| ASCIA | Australasian Society of Clinical Immunology and Allergy |
| ATAGI | Australian Technical Advisory Group on Immunisation |
| BCG | bacille Calmette-Guérin |
| CCID50 | cell culture infectious dose 50% |
| CDNA | Communicable Diseases Network Australia |
| CI | confidence interval |
| CIN | cervical intraepithelial neoplasia |
| CRS | congenital rubella syndrome |
| CSF | cerebrospinal fluid |
| DNA | deoxyribonucleic acid |
| DT | diphtheria-tetanus vaccine |
| dT | diphtheria-tetanus vaccine for use in adults |
| DTPa | diphtheria-tetanus-acellular pertussis vaccine |
| dTpa | diphtheria-tetanus-acellular pertussis vaccine, reduced antigen content formulation |
| DTPw | diphtheria-tetanus-whole-cell pertussis vaccine |
| EIA | enzyme immunoassay |
| EIA | enzyme immunoassay |
| ELISA | enzyme-linked immunosorbent assay |
| FHA | filamentous haemagglutinin |
| FIM | fimbriae (pertussis) |
| GBS | Guillain-Barré syndrome |
| GP | general practitioner |
| GVHD | graft-versus-host disease |
| HAV | hepatitis A virus |
| HBcAg | hepatitis B core antigen |
| HBeAg | hepatitis B e antigen |
| HBIG | hepatitis B immunoglobulin |
| HBsAg | hepatitis B surface antigen |
| HBV | hepatitis B virus |
| HCW | healthcare worker |
| HDCV | human diploid cell vaccine (rabies) |
| HepA | hepatitis A vaccine |
| HepB | hepatitis B vaccine |
| HHE | hypotonic-hyporesponsive episode |
| Hib | Haemophilus influenzae type b |
| Hib-MenCCV | Haemophilus influenzae type b-meningococcal C conjugate vaccine |
| HIV | human immunodeficiency virus |
| HPV | human papillomavirus |
| HRIG | human rabies immunoglobulin |
| HSCT | haematopoietic stem cell transplant |
| HZ | herpes zoster |
| ID | intradermal |
| IgA/G/M | immunoglobulin A/G/M |
| IM | intramuscular |
| IPD | invasive pneumococcal disease |
| IPV | inactivated poliomyelitis vaccine |
| IS | intussusception |
| ITP | idiopathic thrombocytopenia purpura |
| IU | international units |
| IV | intravenous |
| IVIG | intravenous immunoglobulin |
| JE | Japanese encephalitis |
| LT-ETECheat | labile toxin producing enterotoxigenic Escherichia coli |
| MenCCV | meningococcal serogroup C conjugate vaccine |
| MMR | measles-mumps-rubella |
| MMRV | measles-mumps-rubella-varicella |
| NCIRS | National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases |
| NHIG | normal human immunoglobulin |
| NHMRC | National Health and Medical Research Council |
| NIP | National Immunisation Program |
| NSW | New South Wales |
| NT | Northern Territory |
| NTHi | non-typeable Haemophilus influenzae |
| OPV | oral poliomyelitis vaccine |
| PCECV | purified chick embryo cell vaccine (rabies) |
| PCR | polymerase chain reaction |
| PEP | post-exposure prophylaxis |
| pH1N1 | pandemic influenza A(H1N1)pdm09 |
| PHN | post-herpetic neuralgia |
| PI | product information |
| PreP | pre-exposure prophylaxis |
| PRN | pertactin |
| PRP | polyribosylribitol phosphate |
| PRP-OMP | PRP conjugated to the outer membrane protein of Neisseria meningitidis |
| PRP-T | PRP conjugated to tetanus toxoid |
| PT | pertussis toxoid |
| Qld | Queensland |
| RCT | randomised controlled trial |
| RIG | rabies immunoglobulin |
| RNA | ribonucleic acid |
| SA | South Australia |
| SC | subcutaneous |
| SCID | severe combined immunodeficiency |
| SIDS | sudden infant death syndrome |
| SOT | solid organ transplant |
| SSPE | subacute sclerosing panencephalitis |
| Tas | Tasmania |
| TB | tuberculosis |
| TCID50 | tissue culture infectious dose 50% |
| TGA | Therapeutic Goods Administration |
| TIG | tetanus immunoglobulin |
| TST | tuberculin skin test |
| Vic | Victoria |
| VLP | virus-like particle |
| VNAb | (rabies) virus neutralising antibody |
| VPD | vaccine-preventable disease |
| VV | varicella vaccine |
| VZV | varicella-zoster virus |
| WA | Western Australia |
| WHO | World Health Organization |
| ZIG | zoster immunoglobulin |
Page history
Last updated:
8 May 2017
Last reviewed:
18 January 2018